Randomised study of dacarbazine versus dacarbazine plus G3139 (Bcl-2 Antisense Oligonucleotide, Genasense™) in patients with advanced malignant melanoma
Not Applicable
Completed
- Conditions
- Malignant melanoma stages III and IVCancer
- Registration Number
- ISRCTN34651483
- Lead Sponsor
- Genta Incorporated (USA)
- Brief Summary
2006 results in https://www.ncbi.nlm.nih.gov/pubmed/16966688 (added 08/02/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 750
Inclusion Criteria
1. Measurable disease
2. No brain metastases
3. At least 4 weeks since biological therapy, radiation therapy or surgery
4. No previous chemotherapy
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration